Annals of Case Reports and Clinical Studies (ISSN: 2834-5673) | Volume 4, Issue 8 | Case Report | Open Access
Dia Mansukhani*
Dia Mansukhani1*, Malini Chawla1, Arifullah Shaik1, Nahid Anis Shaikh1, Tessy Augustine2, Rania Medhat Seliem1
1Hematology Laboratory, Department of Laboratory Medicine and Pathology, Rashid hospital, Dubai Health, Dubai
2Department of pediatric Hematology-Oncology, Mediclinic hospital, Dubai
*Correspondence to: Dia Mansukhani
Fulltext PDFABSTRACT
Myeloid neoplasms post cytotoxic therapy (MN-pCT)”, previously referred as therapy related AML (t-AML) is a serious complication of cytotoxic cancer treatment for various solid and some hematologic malignancies, though it's uncommon after B-cell Acute Lymphoblastic Leukemia(B-ALL) treatment. This case, involving an 11-year-old boy presenting with AML with emergence of KMT2A (MLL) gene rearrangement while on treatment for ALL, underscores the need for heightened awareness of MN-pCT in ALL survivors. The patient developed AML with monocytic differentiation 18 months after initial B-ALL treatment. The molecular investigation revealed a KMT2A (MLL) gene rearrangement at relapse, which was absent at the time of initial B-ALL diagnosis. This case emphasizes to be aware of MN-pCT development in ALL survivors and optimize monitoring and management decisions.
Acute Lymphoblastic Leukemia; Acute Myeloid leukemia; Flow cytometry; Cytotoxic therapy; KMT2Ar
Dia Mansukhani, Malini Chawla, Arifullah Shaik, Nahid Anis Shaikh, Tessy Augustine, Rania Medhat Seliem. Acute Myeloid Leukemia Post Cytotoxic Therapy in Pediatric B-ALL: A Case Report. Ann Case Rep Clin Stud. 2025;4(8):1-6.